EFFECT OF BODY-WEIGHT ON THE PHARMACOKINETICS OF CYCLOPHOSPHAMIDE IN BREAST-CANCER PATIENTS
EFFECT OF BODY-WEIGHT ON THE PHARMACOKINETICS OF CYCLOPHOSPHAMIDE IN BREAST-CANCER PATIENTS
复制标题
DOI：
10.1007/bf00570489
复制
发表时间：
1987-01-01
影响因子：
3
通讯作者：
INGLE, JN
中科院分区：
文献类型：
--
作者：
POWIS, G;REECE, P;INGLE, JN
对16例晚期乳腺癌女性患者进行了环磷酰胺药代动力学研究。该组包括7名患者，其> 20%，≤ 20%。体重超过理想体重30%者5例，体重超过理想体重30%者5例。环磷酰胺血浆消除半衰期范围为152 - 984 min（平均457 min），表观分布容积为19.1 - 62.3 l（平均36.1 l），血浆清除率为25.9 - 166.6 ml/min（平均69.5 ml/min）。体重与血浆消除半衰期呈显著正相关（r = 0.624，P = 0.010），体重与环磷酰胺清除率呈显著负相关（当归一化至体表面积（r = 0.578，P = 0.019）或归一化至理想体重（r = 0.531，P = 0.0345）时）。表观分布容积与体重无关。结果表明，环磷酰胺的处置是改变患者体重增加。
Cyclophosphamide pharmacokinetics have been studied in 16 female patients with advanced breast cancer. The group included 7 patients who were > 20%, .ltoreq. 30% over ideal body weight and 5 patients who were > 30% over ideal body weight. Cyclophosphamide plasma elimination half-lives ranged between 152 and 984 min (mean 457 min), the apparent volume of distribution between 19.1 and 62.3 1 (mean 36.1 l), and plasma clearance between 25.9 and 166.6 ml/min (mean 69.5 ml/min). There was a significant positive correlation (r = 0.624, P = 0.010) between body weight and plasma elimination half-life, and a significant negative correlation between body weight and cyclophosphamide clearance when normlaized to body surface area (r = 0.578, P = 0.019) or normalized to ideal body weight (r = 0.531, P = 0.0345). The apparent volume of distribution did not correlate with body weight. The results show that cyclophosphamide disposition is altered in patients with increased body weight.